Desjardins Global Asset Management Inc. Sells 344 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Desjardins Global Asset Management Inc. decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 64.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 187 shares of the medical research company’s stock after selling 344 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in IQVIA were worth $43,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in IQV. AdvisorNet Financial Inc grew its holdings in shares of IQVIA by 327.6% in the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after purchasing an additional 95 shares during the last quarter. BKM Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth about $32,000. Activest Wealth Management bought a new stake in shares of IQVIA in the 4th quarter worth about $35,000. Live Oak Investment Partners bought a new stake in shares of IQVIA in the 4th quarter worth about $41,000. Finally, CVA Family Office LLC bought a new stake in shares of IQVIA in the 4th quarter worth about $43,000. Institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock worth $10,331,003 in the last ninety days. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $228.09 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a market cap of $41.40 billion, a PE ratio of 31.29, a PEG ratio of 2.20 and a beta of 1.50. The company’s 50-day moving average is $244.82 and its two-hundred day moving average is $221.65.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. IQVIA’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period last year, the company posted $2.54 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Barclays upped their target price on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Truist Financial upped their price target on shares of IQVIA from $286.00 to $297.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Guggenheim downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. BTIG Research assumed coverage on shares of IQVIA in a research report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price target on the stock. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.